CClinicalTrials.gg
Status unknownNCT04346524Updated Nov 23, 2021

SweMaMi DMI, Microbiome

An observational study in Type 1 Diabetes, sponsored by Karolinska Institutet. Status unknown at 2 sites in Sweden. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by Karolinska Institutet · Observational

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Study summary

Dysbiosis is associated with an increased risk of preeclampsia during pregnancy. The microbiome differs between those with and without type 1 diabetes and the cause of type 1 diabetes has been associated with dysbiosis. Increased knowledge of the microbiome and its variation, depending on the state of health during pregnancies complicated with type 1 diabetes, could in the future lead to preventive care and treatments during these pregnancies.

Read the detailed description

Prospective cohort. All women with type 1 diabetes that are planning a pregnancy and being cared for at the diabetic ward at Södersjukhuset will be asked to participate, n= 55.

All pregnancies complicated with type 1 diabetes that are being cared for at the special maternity ward at Södersjukhuset, n=45.

The expected to include is 100. Expected viable pregnancies: 50.

The maternal vaginal, fecal and oral microbiome will be sampled by "self-sampling" at home before, during and after the pregnancy, by this schedule:

  1. Inclusion, before pregnancy after an appointment with the diabetic doctor or nurse. Or at the first visit at the special maternity care ward during pregnancy (around gestational week 8).
  2. When the pregnancy is first discovered if the inclusion were before pregnancy.
  3. Week 28.
  4. When attending delivery ward in labor
  5. 6-10 weeks postpartum from both the mother and the new-born. The tests will be sent to the obstetric research center at Södersjukhuset, where the tests will be saved in freezes. The analysis will be performed at CTMR at the Karolinska Institute.

Background, pregnancy and delivery data will then be associated with the woman microbiome in the vagina, in feces and in saliva.

02

Conditions studied

  • Type 1 Diabetes

Keywords

  • Type 1 diabetes
  • Microbioma
  • maternal and fetal pregnacy outcomes
03

In context

Diabetes Mellitus, Type 1

3,522 studies on the registry are indexed under Diabetes Mellitus, Type 1; 577 are open to participants now.

This study's planned enrollment of 100 is below the median of 120 across 748 observational studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

pregnant women with type 1 diabetes

Inclusion criteria

  • Pregnant Women with type 1 diabetes
  • Included as a patient at women's clinic Soderhospital in Stockholm
  • Acceptant to sample her microbiome during pregnancy

Exclusion criteria

Exclusion Criteria:

  • Women without type 1 diabetes
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • microbiome sampling

    pregnant women with type 1 diabetes

    Other: sampling of microbiome

Interventions

  • Othersampling of microbiome

    women will sample from vagina, feces, and saliva during pregnancy

06

What researchers measure

Primary outcomes

  1. Maternal complications during pregnancy

    The frequency of Preeklampsia, hypertension and other pregnancy complications

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Fetal complications during pregnancy

    Large for gestational age

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 2 sites recruiting
  • Eva Wiberg-Itzel
    Danderyd, Sverige 18239, Sweden
    Not yet recruiting
  • Eva Wiberg-Itzel
    Stockholm, 18239, Sweden
    • Eva Wiberg-Itzel, Professor · Contact · eva@itzel.eu · +4686163768
    • Per Tornvall, Professor · Contact · per@tornvall.ki · +4686161000
    • Eva Wiberg-Itzel, Professor · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — We have not discussed this question yet

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04346524
Lead sponsor
Karolinska Institutet
Responsible party
Eva Wiberg-Itzel (Associate professor, Karolinska Institutet) — Principal investigator
First posted
Apr 15, 2020
Start date
Apr 1, 2020
Primary completion
Dec 30, 2022 (estimated)
Completion
Dec 30, 2022 (estimated)
Last update
Nov 23, 2021

Study contacts

Eva Wiberg-Itzel, PhD
Contact
eva.itzel@telia.com
+46708775346
Eva Wiberg-Itzel, PhD
principal investigator · Karolinska Institute Sodersjukhuset Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion